ongenital heart disease (CHD), with its worldwide incidence of 0.8%, is the most common inborn heart defect. Advances in pediatric cardiology and cardiac surgery over the past 2 decades resulted in the success that more than 85% of these patients survive to adulthood. 1 As shown recently in a 5-year follow-up survey, the spectrum of young adults with operated CHD (ACHD) consists predominantly of a young population with substantial morbidity but relatively low mortality. 2 As a result of the progress discussed above, patients and clinicians are increasingly confronted with congestive heart failure (CHF) as a Circulation Journal Vol.72, May 2008 late complication of CHD. 3 Medical management of heart failure in these patients represents a challenge because of their complex hemodynamics and the lack of evidencebased guidelines derived from large randomized controlled trials. 4 In adult patients with left ventricular heart failure, a reduction of morbidity and mortality was achieved under neurohormonal blockade. 5, 6 An important question remaining to be solved is, whether or not a similar beneficial effect of -blockade could be observed in ACHD patients, who predominantly have right ventricular heart failure. Thus, we carried out, to the best of our knowledge, the first clinical trial focusing on the use of -blockade during heart failure therapy in ACHD patients. 4, 7 It has been proposed that cytokines are involved in various cardiovascular diseases. [8] [9] [10] [11] Previous results obtained by us and other researchers showed that soluble tumor necrosis factor receptors (sTNF-R) and other cytokines are reduced in adult CHF patients treated with -blockers. [12] [13] [14] [15] [16] [17] [18] From these data it was concluded that cytokines might be involved in, or accompany, the beneficial effects of -blocker therapy. In pre-operated infants with heart failure resulting from left-toright shunts, we showed enhanced sTNF-R concentrations, which were reduced after propranolol treatment. 19 Qing et al showed that in right ventricular tissues of infants with CHD interleukin (IL)-1 , TNF-, IL-6 and IL-10 were detectable. 20 There are also studies reporting that IL-6 and TNF-are enhanced in CHD. [21] [22] [23] However, no studies have shown the influence of -block- Background Right heart failure is a major problem of young adults with congenital heart disease (ACHD) that has been corrected by cardiac surgery. In left ventricular dysfunction (LVD), -blocker therapy improved cytokine concentrations and clinical status. Thus, the effect of bisoprolol on clinical status and plasma cytokine concentrations in ACHD patients with right heart failure after surgical correction for Tetralogy of Fallot was investigated.
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ade on cytokine concentrations and outcome in ACHD patients. In the present study we compared the clinical status, cytokine concentrations, neurohumoral activation and ventricular function in 34 ACHD patients, who had right ventricular heart failure after corrective surgery for Tetralogy of Fallot (TOF), before and after administration of bisoprolol or placebo for 6 months.
Methods

Study Population
A prospective, randomized, double-blind, placebo controlled study was carried out with the -blocker bisoprolol in ACHD patients. In a pilot study from May 2003 to May 2004, we evaluated the cardiocirculatory status of 345 patients with CHD (141 females and 204 males). This group included adolescent and adult patients ranging from 14 to 50 years (median 24.4 years). Of these patients, 94 had undergone surgical correction of TOF. All patients received surgical or interventional therapy of their congenital heart defect in the University Hospital of Göttingen. Patients were consecutively recruited from our out-patient clinic for congenital cardiac disease. For this prospectively designed study we included exercise evaluation, echocardiography, cardiac magnetic resonance imaging (MRI) and the assessment of clinical and neurohormonal variables. The 345 patients were divided according to their cardiac failure as described previously. 24 Heart failure was assumed if the NT-pro brain natriuretic peptide (N-BNP) plasma concentration was significantly elevated (ie, ≥100 pg/ml) [25] [26] [27] and the maximal oxygen uptake was reduced (ie, ≤25 ml·kg -1 · min -1 ). 28 The heart failure criteria defined above were fulfilled by 89 of the 345 (26%) patients. The remaining 256 patients were considered to be non-heart failure patients and were not included in the present study. Patients with significant bradycardia (mean heart rate in Holter electrocardiogram (ECG) <50 /min) or asthma, and patients already onblockade were excluded from the study. Of the 89 patients, we included into the study 34 patients with right ventricular pressure and/or volume overload who underwent surgical correction for TOF (Table 1 ). The first examination of the patients after randomization included Holter ECG, echocardiography, MRI, spiroergometry, cytokine and neurohormonal assessment. According to the CIBIS II protocol, 29 medication was titrated from 1.25 mg/d, 2.5 mg/d, 3.75 mg/d, 5 mg/d, 7.5 mg/d, to 10 mg/d bisoprolol or placebo every 2 weeks up to the highest tolerated dose. Before every augmentation of the dose, the patients were investigated in our outpatient clinic or by the family doctor. Six months after the study entry all patients had their second examination, including the same parameters investigated at study entry.
Informed Consent
After adequate explanation of the purpose of the study, informed consent was obtained from all patients. The protocol was approved by the local ethic committee.
Clinical Investigation
All patients underwent physical examination and measurement of blood pressure (Dinamap 1846, Critikon Corporation, Tampa, FL, USA), body weight and height. A standard 12-lead ECG was recorded to analyse the spontaneous rhythm and the duration of the QRS complex.
Exercise Testing
Exercise testing was done in all patients on an upright bicycle ergometer, beginning with a workload of 0.5 W per kg body weight. The load was increased by 0.5 W per kg every 2 min. Uptake of oxygen was measured using a breathby-breath analysis (Oxycon pro™, Jaeger, Hoechberg, Germany) throughout the procedure. All patients exercised up to their maximal capability. Peak uptake of oxygen was determined as the highest value in the terminal phase of exercise. The 6-lead ECG and heart rate were recorded continuously during the test. Blood pressure was recorded every 2 min using a cuff sphygmomanometer.
Cytokine and Neurohormonal Assessment
Peripheral venous blood samples were obtained from the participants after a rest of at least 15 min, before exercise testing. The blood samples were immediately placed on ice and subsequently centrifuged at 5,000 rpm for 10 min. Plasma and serum aliquots were stored at -80°C until further analysis. N-BNP was determined by immunoassay (Elecsys 2010™, Roche, Germany). N-Terminal atrial natriuretic peptide (N-ANP) and endothelin-1 were determined by enzyme immunoassays (Biomedica, Wien, Austria). Soluble TNF receptors (sTNF-R1 and sTNF-R2, Cytoset, Biosource) and IL-6 (OptEIA, BD Biosciences) enzyme-linked immunosorbent assays were performed according to the manufacturer's instructions.
Echocardiography
We performed cross-sectional and M-mode echocardiography via a transthoracic approach, using a Hewlett Packard Sonos 5500 echocardiograph interfaced with a multifrequency transducer. End-systolic and end-diastolic diameters of the systemic ventricle were measured from a short axis view by M-mode, and fractional shortening was calculated as a parameter for systolic system ventricular function. Fractional change in area, also used as a parameter for systolic ventricular function, was calculated from the cross-sectional measurement of the system ventricle. In addition, we measured the sub pulmonal ventricular end-diastolic diameter from a short axis view by M-mode. The velocities of tricuspid valvar regurgitation were measured by continuous-wave Doppler and served to estimate the sub pulmonal ventricular systolic pressure. We also measured the velocities of flow across the pulmonary valve, using continuouswave Doppler to estimate the degree of the stenosis.
Cardiac MRI
All MRI examinations were performed on a 1.5 Tesla whole body scanner (Magnetom Sonata; Siemens Medical Systems, Erlangen, Germany) equipped with high-performance gradients (maximum amplitude, 30 mT/m; slew rate, 300 mT·m -1 ·ms -1 ). Patients were placed in a supine position and a body phase-array coil was placed over the chest. Standard horizontal and vertical long-axis cine MRI were obtained with a segmented steady-state free precession sequence (TrueFISP, Siemens). All measurements were prospectively gated by using the R wave as a trigger, and were performed using the breath-hold technique. The investigators were blinded with respect to the medications being received by the patients at the time of their evaluation. Three patients in the cohort who had required insertion of pacemakers, as a result of atrio-ventricular block grade 3 postoperatively, were not measured by MRI because of potential complications; they however, remained in the study.
Statistical Analysis
The results are presented as mean ± standard deviation where appropriate. Because most clinical, neurohormonal and echocardiography variables were not normally distributed, non-parametric techniques were used for analysis. The data of every study group (bisoprolol or placebo) at study entry and after 6 months of study medication were analyzed by Wilcoxon matched pair test. For all parameters, a value of p<0.01 was considered statistically significant. The data analyses were performed with SPSS 12.0 (Chicago, IL, USA).
Results
The clinical and demographic data of the patients are shown in Table 1 . The patients were in New York Heart Association (NYHA) class I or II. Five patients received a medical therapy with digoxin and/or diuretics. Because of the former surgical concepts nearly 20 years ago, 24 patients had previously received palliative surgery before corrective surgery at the age of 3.4±3.2 years. According to hypoplasia of the pulmonary valve and arteries, 12 patients needed a transanular patch plastic and 6 patients with pulmonary atresia required a right ventricular to pulmonary artery conduit.
The plasma cytokine and neurohormone concentrations detected in the plasma of the ACHD patients are presented in Table 2 . At the start and during the period of the therapy, N-BNP and N-ANP values were higher than the normal concentrations. After treatment, they were enhanced in the -blocker group; however, they remained unchanged in the placebo group. Endothelin-1 concentrations were also higher than the normal range levels, but were not changed throughout the study in both the placebo and bisoprolol group. Since we have found previously that sTNF receptors were enhanced in CHF patients and reduced after -blocker treatment, 15, 19 we also measured the effect of -blocker therapy on soluble TNF receptor and IL-6 concentrations in the patients included in the present study. The plasma concentrations of IL-6, sTNF-R1 and sTNF-R2 were not enhanced in the tested patients, as compared with normal range and remained at normal concentrations after treatment. The sTNF-R2 concentrations before treatment in the -blocker group were lower than the normal range and the other sTNF values. Thus, compared to this level the sTNF-R2 concentrations after -blocker treatment appeared to be increased. However, they were not different from the normal range and the sTNF-R2 concentrations in the placebo group before and after treatment. Although in the placebo group, the IL-6 concentrations appeared to be slightly enhanced after therapy, all concentrations remained at the normal range. In summary, the data show enhanced concentrations of N-BNP and N-ANP after treatment, but normal range concentrations of sTNF receptors and IL-6. The echocardiographic parameters in the patients assigned to receive bisoprolol, as compared with those receiving placebo were not changed before and after intake of the medication as shown in Table 3 .
Reduced peak oxygen uptake remained unchanged in patients assigned to receive placebo and in those receiving bisoprolol (Table 4) . Furthermore, inspiratory vital capacity and forced expired volume in 1 s were at baseline in both groups. We also observed no effect of -blockade in the spiroergometry measurements. Medication with bisoprolol, however, significantly reduced the heart rate and systolic blood pressure during maximal exercise, indicating an expected consequence of the therapy. Likewise, minimal, average and maximal heart rates as recorded by Holter electrocardiography were significantly reduced following treatment in patients assigned to -blockade (Table 5) .
Functional parameters derived from MRI are shown in Table 6 . Compared with normal range values of healthy adults, 30 all patients had significantly increased end diastolic ventricular volumes and a significantly decreased ejection fraction of the right ventricle at study entry (Table 6 ; ‡). These parameters remained unchanged until the study end. The end diastolic volumes and the ejection fraction of the left ventricle in both the placebo and the -blocker groups also remained unchanged at roughly normal levels during medication.
Discusssion
Many investigations indicated that cytokines are enhanced in chronic heart failure. 15, 21, 23 Some publications showed that -blocker therapy improved ventricular func- tion and that the plasma concentrations of the treated patients contained reduced cytokine concentrations. 5, 16, 31, 32 It has been proposed that cytokines, such as soluble TNF receptors, parallel or mediate the beneficial effects ofadrenoceptor antagonist treatment observed in chronic heart failure patients with LVD. 14, 15 No data exist about the cytokine concentrations and -blocker effect on ventricular function in ACHD with right ventricular volume and/or pressure overload. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study forblocker therapy of heart failure in patients with operated TOF. The present study indicates that -blockade has no visible beneficial effects on clinical and cytokine parameters in TOF patients after 6 months of bisoprolol treatment.
The results measured in the tested TOF patients with right ventricular failure were different from our previous results obtained in patients with LVD. 15 In the previous study, we documented that patients treated with metoprolol had a markedly improved left ventricular ejection fraction and significantly reduced cytokine concentrations. In contrast to these findings, in our present study the ejection fraction of the left ventricle remained unchanged. There was also no improvement of exercise capacity, as measured by peak oxygen consumption, plasma concentrations of cytokines or neurohormones after 6 months of administration of bisoprolol.
Levine and coworkers 33 originally demonstrated that patients with advanced CHF, in particular those who were cachectic, had increased concentrations of circulating TNF. A number of studies have confirmed these findings. [34] [35] [36] More recently, it has been shown that elevated concentrations of cytokine receptors (ie, sTNF-R1 and sTNF-R2) are strong prognostic markers in CHF, suggesting that they might play an important role in its pathogenesis. 37, 38 The concentrations of sTNF receptors in the present study population appeared to remain in the normal range. The question why the soluble TNF receptor concentrations were not elevated in the TOF patients investigated in this study cannot be answered unequivocally. However, because both bisoprolol and metoprolol are considered to be -1-receptor antagonists, the different cytokine response observed in the previous study, as compared with the present study, is probably not caused by pharmcological differences of the 2 substances. Other possible explanations include the severity of the disease, because alterations of cytokine concentrations are most probably associated with high NYHA classes. Thus, the previous patients had NYHA III or IV, and an ejection fraction <40%, whereas in the present study, the patients had a NYHA class of I or II. Also, the difference in mean age between TOF patients and patients with CHF might have contributed, because age-dependent differences of cytokine concentrations can occur. 39 Furthermore, the different pathophysiological mechanisms leading to either heart failure in CHF patients (who have LVD) or TOF patients (predominantly with right ventricular dysfunction) might be differentially influenced or accompanied by cytokines. These results are in accordance with our recently published data, that show no beneficial effects of bisoprolol therapy with regard to clinical and neurohumoral activation. 40 In a multicenter study, Shaddy et al confirmed the lack of positive effect of carvedilol on children with heart defects, probably as a result of the missing benefit on right heart failure. 41 Taken together, we did not observe a reduction of cytokine concentrations in asymptomatic or minimal symptomatic TOF patients treated with bisoprolol. This was paralleled by unimproved heart function, as indicated by unaltered exercise capacity, and unaltered left and right ventricular ejection fraction. These results indicate that the different pathophysiology in left ventricular heart failure and right ventricular heart failure might need different treatment and diagnostic procedures.
Conclusion
This study shows that -blockade did not improve right ventricular function in asymptomatic or minimal symptomatic TOF patients, a finding that was paralleled by unaffected cytokine concentrations. These results indicate that LVD might be targeted by -1-blockers, whereas the same treatment could have less effect in patients who have right heart failure. The primary study endpoints: (1) improvement of the physical efficiency; and (2) improvement of the ventricular pump function, which were derived from earlier studies with LVD patients, were not attainable. Also cytokine concentrations, as the secondary study endpoint, were not improved by -blocker therapy. To find an effective medical treatment for this growing group of young adult patients with heart failure resulting from CHD, more prospective trials need to be done that use more effectiveblockers or drugs that address the differential pathophysiological pathways more appropriate than -blockers.
Study Limitations
One limitation of the study is the low number of patients with higher NYHA class (III and IV), and this was due to the low number of available patients. Furthermore, the time period of 6 months is possibly not long enough to obtain large enough positive effects of the -blockade in TOF patients. An extension of the study was not planned and subsequently not possible. To provide more detailed suggestions about a more beneficial therapeutical approach, further studies with other -blockers or other drugs, such as angiotensin converting enzyme inhibitor inhibitors, are necessary.
